LONDON--( / ) June 08, 2018 -- IBC2018, the world’s most influential media, entertainment and technology show - which last year attracted more than 57,000 attendees from 170 countries - today announces an all-new Telco and Media Innovation Forum to expand its position as one of the preeminent destinations for telecoms and emerging technologies. The collaboration will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018.
IBC2018’s focus on telecoms and smart connectivity comes at a time when the media and telecoms industries are becoming increasingly intertwined. Mirroring this trend, a cross-section of new and long-time IBC exhibitors will showcase the latest breakthroughs set to define both industries.
To reflect the ways in which emerging network technology is changing how the media world operates, IBC2018 will feature the dedicated Telco and Media Innovation Forum designed for the leading players in the industry and a new ‘Smart Connectivity and Multiplay Devices’ track within the IBC Conference Programme in order to provide a platform for collaborative dialogue between telecoms providers, media players and the OTT sector.
The exclusive Telco and Media Innovation Forum will include keynotes from Matt Stagg, Director of Mobile Strategy at BT Sport, Jeremy Fox, Co-founder & CEO, Atrium TV who will discuss how content is developing and how telecoms providers are benefitting from joining their club, and Domingo Corral Lopez, Director of Original Programming, Movistar who will give insight into how his business is developing original content under the wider Telefonica brand. This invitation-only programme will bring together C-suite level audience members to examine the collaboration between telecoms players and content providers, digital transformation, OTT content and current challenges around the evolution of the telecoms sector.
The ‘Smart Connectivity and Multiplay Devices’ track will tackle the challenges and opportunities offered by 5G, exploring the impact the technology will have on broadcasting and beyond. Speakers include Dr David Gomez-Barquero, Senior Researcher, Ramon & Cajal Fellow, Universitat Politecnica de Valencia and Dr Athul Prasad, Head of 5G Business Modelling & Analysis, Nokia - both from the 5G X-Cast consortium - who will deliver a focused masterclass on the future 5G network architecture for live scale immersive media delivery. Nicholas Wodtke, Executive VP, Digital Content, VEON will also give a case study around value added services, the role of content and how traditional mobile services are being disrupted.
IBC2018 is collaborating with the TM Forum - a non-profit industry association for service providers and their suppliers in the telecommunications sector - to increase cooperation and collaboration between their respective industries. TM Forum’s members generate over $2 trillion in revenue and serve five billion customers across 180 countries. The venture will encourage senior executives from both sectors to partner, helping broadcasters, operators and software vendors to work together across the media and telecoms sectors.
“IBC is the go-to destination for media technology professionals, attracting almost 60,000 people to Amsterdam each September. At IBC2018 we are launching the IBC Telco and Media Innovation Forum. Working with the TM Forum and others, IBC will to bring together C-level executives to explore the opportunities and challenges created by convergence,” said IBC CEO Michael Crimp. “We promise our hosted delegates a high-level networking event with world class content. I am sure this will be valuable day for all our guests. I am looking forward to being part of this new initiative.”
“Joining the biggest businesses in the telecoms and media spaces provides me with an opportunity to meet the most influential voices in each field - as a broadcaster looking at the role of mobile and our future, that’s vital,” commented Matt Stagg, Director of Mobile Strategy at BT Sport. “It’s important that events like this break down the silos of technologies and industries - this programme reflects the reality of broadcasting today.”
IBC is the world’s most influential media, entertainment and technology show, attracting 57,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
Conference: 13 - 17 September 2018
Exhibition: 14 - 18 September 2018
For more information about IBC2018 visit: show.ibc.org/
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
두리안 NEWYORK--() April 17, 2013 -- Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its underwritten public offering of 16,375,000 shares of common stock at an offering price of $5.50 per share. Synergy received net proceeds, after deducting the underwriting discount 핫빈 NEWestimated offering expenses, AV다바 시알리스 필름 of approximately $84.5 million. Synergy has also granted the underwriters a 30-day option to purchase up to an additional 2,456,250 shares of common stock to cover over-allotments, if any.
Synergy intends to use the net proceeds from this offering to fund its research and development activities, DC달밤 Synergyfurther clinical development of plecanatide and its other pipeline programs, for working capital, other AV다바 카자마유미 general corporate AV다바 카스미카호 purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.
Credit Suisse, Citigroup and Canaccord Genuity are AV다바 하시모토아리나 acting as book-running 프로토분석 Creditin this offering, and AV다바 후유츠키카에데 Cantor Fitzgerald is acting as a co-manager.
A registration statement relating to the shares AV다바 하하포커 모모세코코아 Aabove was previously filed with and has become effective by rule of the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering was filed 떡치는밤 Athe SEC and is available on the AV다바 남자 건강 보조제 SEC's website at 윙크티비 Aof the final prospectus supplement and related prospectus may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by e-mail at firstname.lastname@example.org; or Citigroup, c/o Broadbridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (800) 831-9146, or by e-mail at email@example.com; or Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone at AV다바 비사정 (617) 371-3900.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the AV다바 securities laws of any such state or 윙크티비 Thisjurisdiction.
윙크티비 AboutAV다바 ERO AboutPharmaceuticals AV다바 배팅토토 Inc.
Synergy is a biopharmaceutical 성인플래시 Synergyfocused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy‘s lead proprietary drug candidate, plecanatide, is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a positive Phase I study of plecanatide in healthy volunteers, and positive Phase IIa and Phase IIb/III clinical trials in patients with chronic idiopathic constipation (CIC). Detailed positive findings from a recently completed 951 patient CIC clinical trial will be AV다바 베팅가이드 presented at a major scientific meeting this year. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy’s second GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel diseases, and is currently in a Phase Ib trial in healthy volunteers having recently completed a Phase Ia trial.Korea Newswire AV다바 스포츠토토카페 distributes your news across every media channels through the industry’s largest press release distribution network